This activity is expired and is no longer available for CME credit.


Neovascular Retinal Disease: Examining Emerging Trends in Treatment

Author(s)/Faculty: Rishi P. Singh, MD; Nathan C. Steinle, MD; Charles C. Wykoff, MD, PhD
Release Date: 9/12/2019Expiration Date: 9/11/2020
Credit Type: CMENumber of Credits: 0
Content Type: LectureProvider:
The integration of intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy into management protocols for the treatment of neovascular retinal disease has revolutionized patient outcomes. However, individualizing dosing schedules to maintain visual acuity gains can be challenging and burdensome to the patient. Furthermore, approximately two-thirds of patients receive a suboptimal response to anti-VEGF therapy, identifying a need for the discovery and classification of novel molecular pathways for targeted therapeutic intervention. In this recorded symposium, experts review the current evidence for the long-term efficacy of treatment and discuss the mechanisms of novel therapies targeting alternative pathways. In addition, they evaluate new evidence for emerging therapies that have the potential to reduce treatment frequency while optimizing visual acuity gains in patients with neovascular retinal disease.